Literature DB >> 11264389

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

T Imamichi1, M A Murphy, H Imamichi, H C Lane.   

Abstract

The potential roles of an amino acid deletion at codon 67 (Delta67) and a Thr-to-Gly change at codon 69 (T69G) in the reverse transcriptase of human immunodeficiency virus (HIV) type 1 in drug sensitivity and relative replication fitness were studied. Our results suggest that the Delta67 and T69G changes can be categorized as mutations associated with multidrug resistance. The combination of both mutations with an L74I change (Delta67+T69G/L74I) leads to a novel 3'-azido-3'-deoxythymidine resistance motif and compensates for impaired HIV replication.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11264389      PMCID： PMC114891          DOI： 10.1128/JVI.75.8.3988-3992.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

1.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Authors:  T Imamichi; T Sinha; H Imamichi; Y M Zhang; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Authors:  P R Meyer; S E Matsuura; A M Mian; A G So; W A Scott
Journal:  Mol Cell       Date:  1999-07       Impact factor: 17.970

5.  The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.

Authors:  L Ross; M Johnson; N Graham; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  1999 Sep-Oct

6.  Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

Authors:  R H Archer; C Dykes; P Gerondelis; A Lloyd; P Fay; R C Reichman; R A Bambara; L M Demeter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.

Authors:  M A Winters; K L Coolley; P Cheng; Y A Girard; H Hamdan; L C Kovari; T C Merigan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.

Authors:  L Ross; M Johnson; R G Ferris; S A Short; L R Boone; T E Melby; R Lanier; M Shaefer; M St Clair
Journal:  J Hum Virol       Date:  2000 May-Jun

9.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157
View more
  13 in total

Review 1.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Authors:  Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Authors:  Rajin Shahriar; Soo-Yon Rhee; Tommy F Liu; W Jeffrey Fessel; Anthony Scarsella; William Towner; Susan P Holmes; Andrew R Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

4.  Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.

Authors:  Anne Derache; Carole L Wallis; Saran Vardhanabhuti; John Bartlett; Nagalingeswaran Kumarasamy; David Katzenstein
Journal:  J Infect Dis       Date:  2015-07-14       Impact factor: 5.226

Review 5.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

6.  Altered strand transfer activity of a multiple-drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutant with a dipeptide fingers domain insertion.

Authors:  Laura A Nguyen; Waaqo Daddacha; Sean Rigby; Robert A Bambara; Baek Kim
Journal:  J Mol Biol       Date:  2011-11-12       Impact factor: 5.469

7.  Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase.

Authors:  Raymond F Schinazi; Ivana Massud; Kimberly L Rapp; Meta Cristiano; Mervi A Detorio; Richard A Stanton; Matthew A Bennett; Monique Kierlin-Duncan; Johan Lennerstrand; James H Nettles
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

8.  Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase.

Authors:  Mónica Kisic; Tania Matamoros; María Nevot; Jesús Mendieta; Javier Martinez-Picado; Miguel A Martínez; Luis Menéndez-Arias
Journal:  J Biol Chem       Date:  2011-04-19       Impact factor: 5.157

Review 9.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

10.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.